RareResearch.AI
← Back to atlas

T686N

Category 3/4 — Most DruggableUncertain significanceLumenal · predictedσ-1 candidateSource card
ThreonineAsparagine at position 686 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type T686 — hydrogen bond to C690
Fullscreen ↗
DynaMut2 mutant · T686N
Mutant N686 — hydrogen bond to T681 lost (2 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

2 lost5 gained14 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondA677Gained
Hydrogen bondT681T681Preserved
Hydrogen bondN682N682Preserved
Hydrogen bondM683M683Preserved
Hydrogen bondL689L689Preserved
Hydrogen bondC690C690Preserved
Polar contactL672Lost
Polar contactA677Gained
Polar contactT681T681Preserved
Polar contactN682N682Preserved
Polar contactM683M683Preserved
Polar contactI688I688Preserved
Polar contactL689L689Preserved
Polar contactC690C690Preserved
Van der WaalsW678Gained
Van der WaalsN682N682Preserved
Van der WaalsM683M683Preserved
Van der WaalsA684Gained
Van der WaalsI688Gained
Van der WaalsL689L689Preserved
HydrophobicA677Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-1.36kcal/mol
Destabilising — moderate
AlphaMissense
0.709
likely pathogenic
AlphaFold pLDDT
90
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsInborn genetic diseases; Optic neuropathy
Population frequency (gnomAD v4)Ultra-rare · AF 0.00074%
cDNA changec.2057C>A
ClinVar accessionVCV002421395
Last evaluated2025/10/14 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — T686N Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Threonine → Asparagine at position 686. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.709, DynaMut2 ΔΔG -1.36 kcal/mol (destabilising).


Identity

FieldValue
VariantT686N (p.Threonine686Asparagine)
DNA changec.2057C>A
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV002421395
Amino acid changeThreonine (T) → Asparagine (N)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 68689.50 — well-folded
DomainC-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position contextC-terminal lumenal domain · position 686 projects into the ER lumen
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 686 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is small polar (threonine — hydroxyl); the mutant is polar amide (asparagine — H-bond donor/acceptor). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.7094
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-1.36 (Destabilising)
Job ID178092125654
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092125654

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Last evaluated2025/10/14 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeT686N is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Inborn genetic diseases
  • Optic neuropathy

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=1.36 < 2 kcal/mol (fold intact) + AlphaMissense 0.709 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=1.36 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.709. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • T686N_molstar_viewer.html — interactive 3D viewer (auto-highlights position 686 with ball-and-stick + neighbors within 5Å)
  • T686N_variant_card.md — this card (source of truth)
  • T686N_variant_card.html — styled printable card
  • T686N_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • T686N_wildtype_interactions.pse / T686N_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the T686N PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download T686N PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.